Visbiome contains the same formulation found in VSL#3®[[[VSL#3® is a registered trademark and is manufactured exclusively for VSL Pharmaceuticals, Inc. Visbiome is manufactured exclusively for ExeGi Pharma and is not affiliated with, endorsed by, or distributed by VSL Pharmaceuticals Inc. ExeGi Pharma, LLC and VSL Pharmaceuticals, Inc. are different companies and have no affiliation with each other.]]](((https://www.visbiome.com/))) produced before January 31, 2016 (the “De Simone Formulation”). In the early 1990s, Professor Claudio De Simone invented The De Simone Formulation, a high potency, eight strain probiotic product intended to aid individuals with gastrointestinal distress. Professor De Simone’s original partners – VSL Pharmaceuticals and its distributors – previously sold his extensively tested probiotic under the name VSL#3®1. In 2016, De Simone severed his relationship with VSL Pharmaceuticals. After June 2016 the VSL#3®1 formulation was changed, and the company then began selling an imitation of the probiotic, instead. They continued to sell its new product under the name VSL#3®1, attempting to pass it off as the same as the original formula, while neglecting to tell customers or physicians about the change. In June 2019, the Court filed a permanent injunction against the distributors of VSL#3®1, preventing them from linking their imitation to the De Simone Formulation in other ways and stop any claims that state or suggest a false continuity between the new VSL#31 and the original De Simone Formulation. The De Simone Formulation, now found in Visbiome, has been the subject of extensive clinical research which cannot be attributed to other probiotics.